Literature DB >> 15240160

Endothelial cell activation by antiphospholipid antibodies.

P L Meroni1, E Raschi, C Testoni, M O Borghi.   

Abstract

Antiphospholipid antibodies are mainly directed against beta 2 glycoprotein I, a phospholipid-binding protein expressed on endothelial cell membranes of different anatomical localizations and recognized by the specific autoantibodies. Antibody binding induces an endothelial activation both in in vitro and in vivo experimental models that might contribute to the prothrombotic state. Endothelial beta 2 glycoprotein I adhesion is mediated by the electrostatic interaction between its cationic phospholipid binding site and anionic structures on the cell membrane; however, binding to annexin II--the endothelial cell receptor for tissue plasminogen activator--plays also a role. Anti-beta-2 glycoprotein I antibodies up-regulate mRNA expression of pro-inflammatory mediators through NF-kappaB translocation and the signaling cascade triggered by Toll-like receptors. Because of the molecular mimicry between beta 2 glycoprotein I and viral/bacterial structures-the natural ligands for Toll-like receptors (TLR)-antibodies might cross-link the molecule associated to the receptors eventually triggering their signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240160     DOI: 10.1016/j.clim.2004.02.015

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  25 in total

Review 1.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

2.  Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome.

Authors:  F Conti; C Alessandri; M Sorice; A Capozzi; A Longo; T Garofalo; R Misasi; D Bompane; G R V Hughes; M A Khamashta; G Valesini
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 3.  Infectious origin of the antiphospholipid syndrome.

Authors:  Y Shoenfeld; M Blank; R Cervera; J Font; E Raschi; P-L Meroni
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

Review 4.  Do antiphospholipid antibodies develop for a purpose?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

5.  The association of anti-phospholipid antibodies with parity in placental malaria.

Authors:  S Owens; L W Chamley; J Ordi; B J Brabin; P M Johnson
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

6.  Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2.

Authors:  Sangeetha Ramesh; Craig N Morrell; Cristina Tarango; Gail D Thomas; Ivan S Yuhanna; Guillermina Girardi; Joachim Herz; Rolf T Urbanus; Philip G de Groot; Philip E Thorpe; Jane E Salmon; Philip W Shaul; Chieko Mineo
Journal:  J Clin Invest       Date:  2010-12-01       Impact factor: 14.808

Review 7.  The roll of Toll-like receptors in the antiphospholipid syndrome.

Authors:  Julia Hurst; Mareike Lorenz; Nadine Prinz; Philipp von Landenberg
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

Review 8.  Update on Antiphospholipid Syndrome: Ten Topics in 2017.

Authors:  Ilaria Cavazzana; Laura Andreoli; Maarteen Limper; Franco Franceschini; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2018-03-15       Impact factor: 4.592

9.  Blocking the glucocorticoid receptor with RU-486 does not prevent glucocorticoid control of autoimmune mouse hearing loss.

Authors:  Dennis R Trune; J Beth Kempton
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

10.  Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

Authors:  Gabriela Cesarman-Maus; Nina P Ríos-Luna; Arunkumar B Deora; Bihui Huang; Rosario Villa; Maria del Carmen Cravioto; Donato Alarcón-Segovia; Jorge Sánchez-Guerrero; Katherine A Hajjar
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.